Table 2.
Baseline patient characteristics for patients alive and disease-free at 12 months (landmark analysis) based on driving time to DF/BWCC.
| Variable | Total patients N. (%)a | ≤40 minutes | 41-159 minutes | ≥160 minutes | p valueb |
|---|---|---|---|---|---|
| Number of patients | 909 | 245 | 440 | 225 | |
| Driving time (median, range in minutes) | 73 (3-356) | ||||
| Number of visits between day 100 and day 365 (median, range) | 11 (0-38) | 14 (0-38) | 11 (0-36) | 8 (0-25) | <0.0001 |
| Age (years) (median, range) | 46 (17-72) | 47 (18-72) | 45 (17-71) | 46 (18-67) | 0.15 |
| Sex | |||||
| Male | 511 (56) | 150 (61) | 241 (55) | 120 (54) | 0.17 |
| Race | 0.0002 | ||||
| Caucasian | 844 (93) | 215 (88) | 414 (94) | 215 (96) | |
| Black/African-American | 21 (2) | 9 (4) | 8 (2) | 4 (2) | |
| Asian | 12 (1) | 10 (4) | 1 (0) | 1 (0) | |
| Other/unknown | 32 (4) | 11 (4) | 17 (4) | 4 (2) | |
| Median household income (median, range in thousands of US$) | 52.1 (16.4-154.4) | 61.3 (26.8-154.4) | 51.7 (16.4-107.9) | 42.6 (25.2-140.7) | <0.0001 |
| Disease | 0.16 | ||||
| AML | 280 (31) | 85 (35) | 125 (28) | 70 (31) | |
| ALL | 83 (9) | 19 (8) | 43 (10) | 21 (9) | |
| CML | 158 (17) | 36 (15) | 83 (19) | 39 (17) | |
| CLL | 67 (7) | 16 (7) | 32 (7) | 19 (8) | |
| MDS | 92 (10) | 24 (10) | 41 (9) | 27 (12) | |
| MPDc | 12 (1) | 3 (1) | 5 (1) | 4 (2) | |
| Low grade NHLh | 40 (4) | 9 (4) | 23 (5) | 8 (4) | |
| High grade NHLi | 79 (9) | 34 (14) | 34 (8) | 11 (5) | |
| HL | 33 (4) | 6 (2) | 18 (4) | 9 (4) | |
| MM | 23 (3) | 1 (0) | 16 (4) | 6 (3) | |
| Benign hematologic disease | 39 (4) | 11 (4) | 18 (4) | 10 (4) | |
| Otherd | 3 (0) | 1 (0) | 2 (0) | 0 (0) | |
| Stage at SCT | 0.74 | ||||
| CR1/CP1 | 346 (38) | 90 (37) | 166 (38) | 90 (40) | |
| CR>1/CP>1 | 130 (14) | 36 (15) | 68 (15) | 16 (12) | |
| Induction Failure | 109 (12) | 33 (13) | 53 (12) | 23 (10) | |
| PR/AP | 143 (16) | 36 (15) | 75 (17) | 32 (14) | |
| Relapse/BC | 74 (8) | 20 (8) | 31 (7) | 23 (10) | |
| Untreated | 107 (12) | 30 (12) | 47 (11) | 30 (13) | |
| Treatment on protocol | 0.28 | ||||
| Yes | 450 (50) | 111 (45) | 222 (50) | 117 (52) | |
| ECOG performance status at SCTe | 0.46 | ||||
| 0 | 241 (50) | 64 (46) | 119 (52) | 58 (50) | |
| 1 | 200 (42) | 64 (46) | 86 (38) | 50 (43) | |
| 2-3 | 39 (8) | 10 (7) | 22 (10) | 7 (6) | |
| Donor match | 0.45 | ||||
| MRD | 428 (47) | 109 (44) | 206 (47) | 113 (50) | |
| Non-MRD | 481 (53) | 136 (56) | 234 (53) | 111 (50) | |
| MUD | 372 (41) | 98 (40) | 184 (42) | 90 (40) | |
| MM | 109 (12) | 38 (16) | 50 (11) | 21 (9) | |
| Mismatched URD | 97 (11) | 35 (14) | 44 (10) | 18 (8) | |
| Mismatched relative | 12 (1) | 3 (1) | 6 (1) | 3 (1) | |
| Graft source | 0.16 | ||||
| PB | 543 (60) | 156 (64) | 254 (58) | 133 (59) | |
| BM | 319 (35) | 72 (29) | 164 (37) | 83 (37) | |
| PB+BM | 4 (0) | 1 (0) | 1 (0) | 2 (1) | |
| UCB | 43 (5) | 16 (7) | 21 (5) | 6 (3) | |
| Conditioning | 0.049 | ||||
| NMA/RIC | 296 (33) | 95 (39) | 131 (30) | 70 (31) | |
| GVHD prophylaxis | 0.24 | ||||
| CnI +/- Mtx | 406 (45) | 100 (41) | 197 (45) | 109 (49) | |
| CnI + Rapa +/- Mtx | 355 (39) | 105 (43) | 174 (40) | 76 (34) | |
| CnI + MMF | 32 (4) | 13 (5) | 13 (3) | 6 (3) | |
| T-cell depletion | 104 (11) | 25 (10) | 48 (11) | 31 (14) | |
| Other | 12 (1) | 2 (1) | 8 (2) | 2 (1) | |
| CMV serostatusf | 0.52 | ||||
| Recipient or donor + | 522 (59) | 146 (61) | 253 (59) | 98 (56) | |
| Sex matchingg | 0.042 | ||||
| Mismatched | 420 (46) | 128 (52) | 186 (42) | 106 (48) | |
| GVHD cum incidence | |||||
| Acute GVHD 2-4 | 24% | 26% | 24% | 23% | 0.6 |
| Acute GVHD 3-4 | 7% | 6% | 7% | 8% | 0.7 |
| Chronic GVHD | 52% | 57% | 51% | 48% | 0.062 |
| Year of SCT (median, range) | 2004 (1996-2009) | 2004 (1996-2009) | 2004 (1996-2009) | 2004 (1996-2009) | 0.070 |
| Months of follow-up for survivors (median, range) | 48 (12-163) | 48 (12-150) | 49 (12-148) | 48 (12-163) | 0.87 |
a
Percentages may not add to 100 because of rounding
b
By Kruskal-Wallis test for continuous variables and chi-square test for discrete variables.
c
Including mixed MPD/MDS
e
Data missing on 429 patients
f
Recipient or donor status missing on 20 patients
g
Sex donor missing on 2 patients
h
Low grade NHL includes:Follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma.
i
High grade NHL includes all histologies not found in low grade NHL